Aura Biosciences, Inc. (NASDAQ: AURA) stands out in the biotechnology sector not only for its innovative approach to treating solid tumors but also for the significant growth potential it offers to investors. With a market capitalization of $356.89 million, Aura is a clinical-stage biotech firm that specializes in developing precision therapies using a proprietary platform of virus-like drug conjugates. The company’s lead candidate, bel-sar, is at the forefront of their research efforts, targeting primary choroidal melanoma and exploring applications in bladder cancer.

Despite its innovative pipeline, Aura’s current stock price sits at $5.62, marking the lower end of its 52-week range of $4.90 to $7.95. This price stability…